{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:00:41Z","timestamp":1790092841953,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05939-w","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:38:37Z","timestamp":1790044717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regimen-stratified Bayesian model-based meta-analysis of targeted biologics in generalised myasthenia gravis: efficacy comparison, mechanism-level class contrast, and endpoint sensitivity with model-informed trial design"],"prefix":"10.1007","author":[{"given":"Sayantan Shankar","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswa Mohan","family":"Padhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Anil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Hota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0663-0922","authenticated-orcid":false,"given":"Anand","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Wasnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"6","key":"5939_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K (2022) Current treatment of myasthenia gravis. J Clin Med 11(6):1597. https:\/\/doi.org\/10.3390\/jcm11061597","journal-title":"J Clin Med"},{"issue":"2","key":"5939_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S, Nowak RJ, Farmakidis C, Bril V et al (2025) Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol 24(2):105\u2013116. https:\/\/doi.org\/10.1016\/S1474-4422(24)00498-8","journal-title":"Lancet Neurol"},{"key":"5939_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW (1998) Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 841:769\u2013772. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb11015.x","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"5939_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/psp4.12041","volume":"5","author":"M Boucher","year":"2016","unstructured":"Boucher M, Bennetts M (2016) The many flavors of model-based meta-analysis: part I\u2014introduction and landmark data. CPT Pharmacomet Syst Pharmacol 5(2):54\u201364. https:\/\/doi.org\/10.1002\/psp4.12041","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5","key":"5939_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/psp4.12299","volume":"7","author":"M Boucher","year":"2018","unstructured":"Boucher M, Bennetts M (2018) Many flavors of model-based meta-analysis: part II\u2014modeling summary-level longitudinal responses. CPT Pharmacometrics Syst Pharmacol 7(5):288\u2013297. https:\/\/doi.org\/10.1002\/psp4.12299","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"5939_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22(5):383\u2013394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"issue":"1","key":"5939_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v080.i01","volume":"80","author":"PC B\u00fcrkner","year":"2017","unstructured":"B\u00fcrkner PC (2017) brms: an R package for Bayesian multilevel models using Stan. J Stat Softw 80(1):1\u201328. https:\/\/doi.org\/10.18637\/jss.v080.i01","journal-title":"J Stat Softw"},{"issue":"1","key":"5939_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA (2021) The epidemiology of myasthenia gravis. J Med Life 14(1):7\u201316. https:\/\/doi.org\/10.25122\/jml-2020-0145","journal-title":"J Med Life"},{"issue":"1","key":"5939_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v076.i01","volume":"76","author":"B Carpenter","year":"2017","unstructured":"Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M et al (2017) Stan: a probabilistic programming language. J Stat Softw 76(1):1\u201332. https:\/\/doi.org\/10.18637\/jss.v076.i01","journal-title":"J Stat Softw"},{"issue":"8","key":"5939_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/psp4.12811","volume":"11","author":"C Chen","year":"2022","unstructured":"Chen C, Lavezzi SM, Iavarone L (2022) The area under the effect curve as an efficacy determinant for anti-infectives. CPT Pharmacomet Syst Pharmacol 11(8):1029\u20131044. https:\/\/doi.org\/10.1002\/psp4.12811","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"5939_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1280226","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Qiu Y, Yin Z, Wang Z, Tang Y, Ni H et al (2023) Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. Front Immunol 14:1280226. https:\/\/doi.org\/10.3389\/fimmu.2023.1280226","journal-title":"Front Immunol"},{"issue":"10","key":"5939_CR12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"1","key":"5939_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05751-1","volume":"22","author":"J Gu","year":"2024","unstructured":"Gu J, Qiao Y, Huang R, Cong S (2024) Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis. J Transl Med 22(1):955. https:\/\/doi.org\/10.1186\/s12967-024-05751-1","journal-title":"J Transl Med"},{"issue":"12","key":"5939_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16490","volume":"31","author":"AA Habib","year":"2024","unstructured":"Habib AA, Benatar M, Vu T, Meisel A, Attarian S, Katsuno M et al (2024) Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Eur J Neurol 31(12):e16490. https:\/\/doi.org\/10.1111\/ene.16490","journal-title":"Eur J Neurol"},{"issue":"2","key":"5939_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(24)00514-3","volume":"24","author":"AA Habib","year":"2025","unstructured":"Habib AA, Zhao C, Aban I, Fran\u00e7a MC Jr, Jos\u00e9 JG, Meyer Zu H\u00f6rste G et al (2025) Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 24(2):117\u2013127. https:\/\/doi.org\/10.1016\/S1474-4422(24)00514-3","journal-title":"Lancet Neurol"},{"key":"5939_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ (eds) (2019) Cochrane handbook for systematic reviews of interventions, 2nd ed. Wiley-Blackwell, Chichester, UK. https:\/\/doi.org\/10.1002\/9781119536604","edition":"2nd ed"},{"issue":"12","key":"5939_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"issue":"5","key":"5939_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard","year":"2020","unstructured":"Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL et al (2020) Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol 77(5):582\u2013592. https:\/\/doi.org\/10.1001\/jamaneurol.2019.5125","journal-title":"JAMA Neurol"},{"issue":"7","key":"5939_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"issue":"5","key":"5939_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22(5):395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"issue":"6","key":"5939_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10928-024-09937-4","volume":"51","author":"C Hu","year":"2024","unstructured":"Hu C, Kondic AG, Roy A (2024) Visual predictive check of longitudinal models and dropout. J Pharmacokinet Pharmacodyn 51(6):859\u2013875. https:\/\/doi.org\/10.1007\/s10928-024-09937-4","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"414","key":"5939_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208","volume":"9","author":"P Kiessling","year":"2017","unstructured":"Kiessling P, Lledo-Garcia R, Watanabe S, Langdon G, Tran D, Bari M et al (2017) The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med 9(414):eaan1208. https:\/\/doi.org\/10.1126\/scitranslmed.aan1208","journal-title":"Sci Transl Med"},{"issue":"1","key":"5939_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","volume":"4","author":"LL Kusner","year":"2008","unstructured":"Kusner LL, Kaminski HJ, Soltys J (2008) Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Rev Clin Immunol 4(1):43\u201352. https:\/\/doi.org\/10.1586\/1744666X.4.1.43","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"5939_CR24","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1208\/s12248-015-9808-7","volume":"17","author":"A Largajolli","year":"2015","unstructured":"Largajolli A, Bertoldo A, Campioni M, Cobelli C (2015) Visual predictive check in models with time-varying input function. AAPS J 17(6):1455\u20131463. https:\/\/doi.org\/10.1208\/s12248-015-9808-7","journal-title":"AAPS J"},{"issue":"2","key":"5939_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","volume":"38","author":"Y Ma","year":"2024","unstructured":"Ma Y, Nie X, Zhu G, Qi W, Hao L, Guo X (2024) The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis. CNS Drugs 38(2):93\u2013104. https:\/\/doi.org\/10.1007\/s40263-024-01062-7","journal-title":"CNS Drugs"},{"issue":"8","key":"5939_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/psp4.12091","volume":"5","author":"D Mawdsley","year":"2016","unstructured":"Mawdsley D, Bennetts M, Dias S, Boucher M, Welton NJ (2016) Model-based network meta-analysis: a framework for evidence synthesis of clinical trial data. CPT Pharmacomet Syst Pharmacol 5(8):393\u2013401. https:\/\/doi.org\/10.1002\/psp4.12091","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"9","key":"5939_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN (2012) Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 1(9):e6. https:\/\/doi.org\/10.1038\/psp.2012.4","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"5939_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60(1):14\u201324. https:\/\/doi.org\/10.1002\/mus.26447","journal-title":"Muscle Nerve"},{"issue":"3","key":"5939_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2020","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al (2020) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"issue":"23","key":"5939_CR30","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","volume":"392","author":"RJ Nowak","year":"2025","unstructured":"Nowak RJ, Benatar M, Ciafaloni E, Howard JF, Leite MI, Utsugisawa K et al (2025) A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med 392(23):2309\u20132320. https:\/\/doi.org\/10.1056\/NEJMoa2501561","journal-title":"N Engl J Med"},{"issue":"12","key":"5939_CR31","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, Sormani MP, Signori A (2023) Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol 30(12):3854\u20133867. https:\/\/doi.org\/10.1111\/ene.15872","journal-title":"Eur J Neurol"},{"issue":"2","key":"5939_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JPA (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163\u2013171. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"5939_CR33","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/acn3.52051","volume":"11","author":"D Tokuyasu","year":"2024","unstructured":"Tokuyasu D, Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S et al (2024) Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Ann Clin Transl Neurol 11(5):1338\u20131346. https:\/\/doi.org\/10.1002\/acn3.52051","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"5939_CR34","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E et al (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 128(10):4372\u20134386. https:\/\/doi.org\/10.1172\/JCI97911","journal-title":"J Clin Invest"},{"issue":"5","key":"5939_CR35","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s11222-016-9696-4","volume":"27","author":"A Vehtari","year":"2017","unstructured":"Vehtari A, Gelman A, Gabry J (2017) Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Stat Comput 27(5):1413\u20131432. https:\/\/doi.org\/10.1007\/s11222-016-9696-4","journal-title":"Stat Comput"},{"issue":"5","key":"5939_CR36","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R et al (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid 1(5):EVIDoa2100066. https:\/\/doi.org\/10.1056\/EVIDoa2100066","journal-title":"NEJM Evid"},{"issue":"2","key":"5939_CR37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1214\/20-BA1221","volume":"16","author":"A Vehtari","year":"2021","unstructured":"Vehtari A, Gelman A, Simpson D, Carpenter B, B\u00fcrkner PC (2021) Rank-normalization, folding, and localization: an improved R\u0302 for assessing convergence of MCMC (with discussion). Bayesian Anal 16(2):667\u2013718. https:\/\/doi.org\/10.1214\/20-BA1221","journal-title":"Bayesian Anal"},{"issue":"1","key":"5939_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM (2011) Myasthenic crisis. Neurohospitalist 1(1):16\u201322. https:\/\/doi.org\/10.1177\/1941875210382918","journal-title":"Neurohospitalist"},{"issue":"7","key":"5939_CR39","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487\u20131489. https:\/\/doi.org\/10.1212\/WNL.52.7.1487","journal-title":"Neurology"},{"key":"5939_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2024.100541","volume":"37","author":"GI Wolfe","year":"2024","unstructured":"Wolfe GI, Hanson JE, Silvestri NJ (2024) Myasthenia gravis: the evolving therapeutic landscape. eNeurologicalSci 37:100541. https:\/\/doi.org\/10.1016\/j.ensci.2024.100541","journal-title":"eNeurologicalSci"},{"issue":"5","key":"5939_CR41","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/mus.70013","volume":"72","author":"W Wu","year":"2025","unstructured":"Wu W, Petersson M, Piehl F, Brauner S (2025) Comparison of the Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scores from a clinical practice perspective. Muscle Nerve 72(5):1100\u20131107. https:\/\/doi.org\/10.1002\/mus.70013","journal-title":"Muscle Nerve"},{"issue":"4","key":"5939_CR42","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","volume":"81","author":"C Yan","year":"2024","unstructured":"Yan C, Yue Y, Guan Y, Bu B, Ke Q, Duan R et al (2024) Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial. JAMA Neurol 81(4):336\u2013345. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0044","journal-title":"JAMA Neurol"},{"key":"5939_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1479685","volume":"15","author":"H Zhong","year":"2024","unstructured":"Zhong H, Li Z, Li X, Wu Z, Yan C, Luo S et al (2024) Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis. Front Neurol 15:1479685. https:\/\/doi.org\/10.3389\/fneur.2024.1479685","journal-title":"Front Neurol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05939-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:07:48Z","timestamp":1790089668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05939-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":43,"alternative-id":["5939"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05939-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"7 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is an MBMA of aggregate-level data from previously published clinical trials and did not involve the recruitment of human participants, the collection of individual patient data, or the use of animals. Accordingly, an ethical waiver was obtained.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}